Aziclar (clarithromycin) acts by binding to the 50S ribosomal subunit of susceptible bacteria, which inhibits protein biosynthesis.

Yes, it exhibits a bactericidal effect against H. pylori, particularly at neutral pH, and is indicated for use in combination with other medicinal agents for ulcer treatment.

Yes, concomitant use is contraindicated with astemizole, cisapride, pimozide, terfenadine, ergot alkaloids, HMG-CoA reductase inhibitors (lovastatin or simvastatin), oral midazolam, lomitapide, ticagrelor, ivabradine, and ranolazine.

For patients with severe renal failure (creatinine clearance <30 ml/min), the dose should be decreased by 50%.